Can Asia Build a Technology Layer for Its Fragmented Pharmaceutical Supply Chains?

Across Asia, pharmaceutical distribution remains fragmented by geography, regulation and local networks. Digital platforms are beginning to improve procurement, inventory and traceability, but the bigger opportunity may be building interoperable infrastructure that connects local systems without trying to replace them.

Asia’s pharmaceutical supply chains are becoming more important, but not necessarily more integrated. Southeast Asia’s healthcare distribution market, covering pharmaceuticals and medical devices, is projected to grow from about $18 billion in 2023 to $26 billion by 2029, according to BDA Partners. Pharmaceutical distribution alone is estimated to reach $16.4 billion in 2025. Yet the region remains highly fragmented, with distributors deriving much of their competitive advantage from local regulatory knowledge, logistics capabilities and relationships with suppliers and customers.

That fragmentation creates a problem that technology can address, but not entirely eliminate. Manufacturers need visibility into demand, distributors need better inventory management, pharmacies need reliable procurement, and regulators increasingly need traceability. At the same time, pharmaceutical markets operate under different licensing regimes, pricing structures, distribution networks and data systems.

The opportunity, therefore, may not be to build one Asian pharmaceutical distribution model. It may be to build a technology layer that allows many local systems to work more efficiently together.

Pharmaceutical distribution is becoming a data problem

Traditional pharmaceutical distribution has been built around physical infrastructure: warehouses, distributors, transport networks and pharmacy relationships. Those remain essential, but a more complex healthcare market requires something else: visibility.

Knowing how much medicine is available is only one part of the problem. Supply chains increasingly need to understand where products are, how quickly they are moving, where demand is emerging, and whether medicines can be traced back through authorized channels.

The stakes are particularly high because supply-chain complexity can create public-health risks. The World Health Organization estimates that at least one in 10 medicines in low- and middle-income countries are substandard or falsified. It identifies complex supply chains, weak regulatory systems and informal markets among the factors that allow these products to enter circulation.

That makes technologies for ordering, inventory management, demand forecasting and traceability more than efficiency tools. They can become part of the infrastructure supporting medicine quality and access.

Asia’s fragmentation is both the problem and the opportunity

The challenge is that the underlying need may be universal while the operating environment is not.

Kazi Ashikur Rasul, Co-founder and CEO of PulseTech, described this distinction while conversing with AsiaTechDaily: “The core need is universal: pharmaceutical companies everywhere need reliable distributors to get authentic medicines to pharmacies efficiently. That part of the model transfers directly. What’s also transferable is our technology-enabled distribution approach: the systems we use to manage ordering, inventory, and deliveries; the data discipline around demand forecasting and the way we layer on services like financing and pharmacy software. Those are built to be adapted, not reinvented, in each new market.”

“What needs to be rebuilt locally is the market-specific layer: regulations and licensing, pricing dynamics, and relationships with key stakeholders, pharmaceutical companies, pharmacies, and regulators. That’s why we intend to enter international markets via partnerships with local distributors. The distribution need and our technology are the constants; our local partners help us handle everything specific to each market. Because we deeply understand the pharmaceutical market and operate in a data-driven way, we can test and iterate our systems easily, as we expand.”

That distinction is important for healthtech companies attempting to expand internationally. Unlike pure software, pharmaceutical distribution cannot simply be copied into another market. Technology can travel, but physical networks, licenses, regulatory relationships and local trust have to be established again.

Indonesia provides one example of how this could work at a national level. The country’s Ministry of Health has been developing SATUSEHAT Logistics as part of its broader digital health infrastructure, while the SMILE logistics system provides real-time monitoring of medical supplies and inventory. The objective is not simply to create another digital marketplace. It is to improve visibility across pharmaceutical and medical-product logistics. UNDP has described the digitalization of Indonesia’s health-supply chain as a way to address data fragmentation, stockouts and inefficient inventory management.

The lesson is broader than Indonesia: digital infrastructure can sit underneath existing healthcare systems rather than requiring every participant to migrate to one platform. That model becomes particularly relevant across Asia, where replacing established distributors is often unrealistic.

Private markets are assembling the pieces

The private sector is also moving toward technology-enabled distribution. In India, CureBay acquired Saveo Healthtech’s B2B pharmaceutical distribution business in March 2026. Saveo’s network served more than 10,000 retail pharmacies across southern India and included physical distribution hubs, procurement capabilities and digital ordering systems. CureBay said the integration would improve inventory visibility and demand planning while combining its healthcare network with Saveo’s supply infrastructure.

The development illustrates an important reality: digital pharmaceutical distribution still needs physical distribution. Technology can improve procurement, forecasting and fulfillment, but warehouses, transportation and pharmacy relationships remain indispensable. Across Southeast Asia, companies such as SwipeRx and Medlink have similarly focused on connecting pharmacies, pharmaceutical companies and distribution functions through digital platforms. Together, these developments suggest the market is moving beyond the simple digitization of pharmacy transactions toward a broader infrastructure question.

The strongest opportunity may therefore lie between the manufacturer and the pharmacy, rather than at either end.

A mature technology layer could connect:

• manufacturers and distributors through procurement and demand data
• distributors and pharmacies through digital ordering and inventory visibility
• supply chains and regulators through traceability and compliance data
• pharmacies and financial providers through transaction and working-capital information

The resulting data could create a feedback loop. Better pharmacy-level demand data can improve forecasting. Better forecasting can reduce overstocking and stockouts. More reliable transaction records can improve financing decisions. Greater visibility can also make it easier to identify irregularities in the supply chain. But interoperability remains difficult. Different countries use different regulatory systems, product identifiers, data standards and pharmacy software. Even within individual healthcare systems, fragmented digital infrastructure can prevent information from flowing efficiently. That means the technology layer will need to be built around common standards and APIs, not simply another closed platform.

Local partnerships will remain critical

Asia’s pharmaceutical supply chains are unlikely to become uniform. Nor should they. The more realistic model is one where technology standardizes what can be standardized, while local partners manage what cannot. Regulatory compliance, licensing, pricing, distribution relationships and physical fulfillment will continue to require country-specific expertise.

This could reshape how healthtech companies think about international expansion. Instead of exporting an entire operating model, startups may increasingly export their technology, data architecture and processes while partnering with established local distributors. The distinction is crucial. A technology company can make inventory data portable. It cannot make Indonesian, Indian, Vietnamese or Bangladeshi pharmaceutical regulation interchangeable.

Asia does not necessarily need a single pharmaceutical supply chain. It needs better connections between the thousands of systems that already exist. As pharmaceutical markets expand, the value of digital infrastructure will increasingly be measured not by whether it replaces distributors, but by whether it gives manufacturers, distributors, pharmacies and regulators a clearer view of what is happening across the chain.

The most consequential healthtech companies may therefore operate largely behind the scenes. Their products may not be the digital pharmacy consumers see, but the infrastructure that determines whether that pharmacy has the right medicine, at the right time, from a verifiable source. For Asia’s fragmented healthcare markets, the winning model may not be standardization of the supply chain itself, but standardization of the technology that allows those supply chains to communicate.

Quick Takeaways

• Asia’s pharmaceutical supply chains are growing but remain fragmented across countries, distributors, pharmacies, regulations and logistics networks.
• The biggest opportunity may be a shared technology layer, rather than trying to build one standardized regional distribution system.
• Digital tools can improve ordering, inventory, demand forecasting and traceability, making pharmaceutical distribution increasingly a data infrastructure problem.
• Technology can travel more easily than healthcare operations. Licensing, pricing, regulatory relationships, warehouses and local distribution networks still need market-specific solutions.
• Indonesia offers an important blueprint through digital health and logistics infrastructure designed to improve supply-chain visibility.
• India and Southeast Asia are seeing private-sector innovation around B2B pharmaceutical procurement, pharmacy networks and digital distribution.
• Traceability is becoming a public-health issue, not just an efficiency concern, given the risks posed by substandard and falsified medicines.
• Interoperability could become the next major challenge. Different data standards, regulatory systems and pharmacy software can limit the benefits of digitization.
• Local partnerships will remain essential. Healthtech companies can export technology and operating systems, but local distributors remain critical for navigating country-specific markets.
• The long-term opportunity is infrastructure, not another marketplace: technology that connects manufacturers, distributors, pharmacies and regulators could become a foundational layer for Asia’s pharmaceutical supply chains.